INTRODUCTION
Thus, disruption of PR function is an excellent target for the design of protease-specific antiviral agents. Indeed, Retroviruses are important disease-causing agents in the HIV-1-encoded protease (HIV-1 PR) (Kramer et al., man and animals. Most notable is the human immunode-1986) is one of most important current targets for strucficiency virus (HIV-1), which causes acquired immunodeture-based drug design (Huff, 1991) , with the aim of deficiency syndrome (AIDS) in humans (Ratner et al., 1985) .
veloping potential therapeutics for AIDS. We have preFeline immunodeficiency virus (FIV) infection is wideviously defined the sites of the FIV PR-catalyzed cleavspread in domestic and wild cat populations and has ages that lead to processing of the FIV Gag and Gag-Pol been shown to induce an AIDS-like syndrome, with propolyproteins to give the structural proteins and enzymes, gression and severity similar to AIDS in humans (Ackley including the protease which is involved in virus matura Barlough et al., 1991; Dow et al., 1990 ; Ishida tion and infection (Elder et al., 1993 Pedersen et al., 1987; Yamamoto et al., 1988, In the present study, we describe the total chemical 1989, 1991) . Molecular studies of FIV have defined the synthesis of FIV PR, and the determination of its enzysequence and organization of the viral genome and dematic activities. The results of this initial investigation of termined that FIV was a lentivirus, similar in genetic orgathe comparative enzymatic properties of the FIV PR and nization to HIV-1 (Elder et al., 1993; Olmstead et al., 1989;  HIV-1 PR indicate differences in specificity for the two Phillips et al., 1990; . Because of the PRs and in substrate length requirements. Such comparisimilarity of the two viruses and associated diseases at sons facilitate the refining of our understanding of how the molecular level, the study of FIV is potentially imthe viral PRs function and may suggest avenues to the portant for the understanding of HIV and for therapeutic development of more effective PR inhibitors. intervention in AIDS.
Retroviruses encode a protease (PR) involved in viral MATERIALS AND METHODS maturation (Crawford et al., 1985; Katoh et al., 1985; Ashorn et al., 1990) that is essential for viral infectivity (Katoh Peptide synthesis et al., 1985; Kohl et al., 1988; Baboonian et al., 1991) .
Machine-assisted stepwise solid phase syntheses were carried out on a 0.2 mmol scale using Boc chemis-scribed (Schnölzer et al., 1992a) . Synthesis of the 116-Assay of enzymatic activity residue FIV PR polypeptide chain was carried out on Assays were carried out at 37Њ in 0.05 M sodium cia Boc-Met-OCH 2 -Pam resin (Applied Biosystems, Foster trate/0.1 M sodium phosphate buffer, pH 5.25, containing City, CA). Peptide substrates were synthesized manually 0.1 mM EDTA, 1 mM DTT, and 1 M NaCl. The peptide on 4-MeBHA resin (Peninsula Laboratories Inc., Belmont, substrates were dissolved in DMSO at a concentration CA) and were acetylated at their N-terminus with a soluof 20 mg/ml, diluted 20-fold into assay buffer, and then tion of 20% acetic anhydride/5% DIEA in DMF for 10 min.
1:1 into the reaction mixture. The final concentration of Product peptide resins were deprotected and the free substrates in the reaction mixture was 0.5 mg/ml. For a peptides were released from the resin by cleavage with 20-ml assay, 2 ml of the above enzyme solution was used. HF as previously described (Schnölzer et al., 1992a) . The
The progress of the cleavage reaction was followed by crude peptides were precipitated and washed with icereverse-phase HPLC on a Vydac C 18 column (0.46 1 15 cold diethyl ether, dissolved in 20-70% aqueous acetic cm) at a flow rate of 1 ml/min using a linear gradient acid, diluted with H 2 O, and lyophilized. from 0 to 40% acetonitrile in 0.1% aqueous TFA over 15 min. Cleavage products were collected from analytical Characterization of synthetic peptides HPLC runs based on their absorbance at 214 nm and Crude peptide products were analyzed by reversedirectly analyzed by electrospray mass spectrometry phase HPLC using a Vydac C 18 column (0.46 1 15 cm) without further manipulation. at a flow of 1 ml/min with a linear gradient from 0.1%
Effect of salt concentration. Standard cleavage assays aqueous TFA to 65% acetonitrile/35% water containing with the 21-residue MA/CA peptide substrate were car-0.1% TFA. Sample absorbance was recorded at 214 nm.
ried out at NaCl concentrations from 0 to 5 M. QuantitaSemipreparative HPLC was carried out on a Vydac C 4 tion of cleavage products after an incubation time of 1 column (1.0 1 25 cm) using linear solvent gradients on hr at 37Њ was based on integration of peak areas oba Waters Delta Prep 4000 HPLC system. Solvents A and tained by analytical HPLC. B were as described above. The concentration of buffer pH dependence. Assays (10 ml) were carried out at B in A was linearly increased at a rate of 1% per minute different pH using 5 mg of the 21-residue MA/CA peptide at a flow rate of 3 ml/min. Absorbance was recorded at substrate and 1 ml PR solution. The pH was varied in 220 nm. steps of 0.5 pH units by mixing different amounts of 0.1 Peptide products, both crude and purified, were also M sodium citrate/0.2 M Na 2 HPO 4 buffers containing 0.1 characterized by electrospray mass spectrometry (Model mM EDTA and 1 mM DTT. Quantitation of product forma-API III, Sciex, Thornhill, Ontario, Canada). Peptides were tion after a 20-min incubation time was done by HPLC dissolved in either 50% acetic acid or 50% water/acetonias described above. trile/0.1% TFA to a concentration of 1 mg/ml. Samples Measurement of kinetic parameters. V max and K m for were introduced into the atmospheric pressure ionization the cleavage of the 21-residue MA/CA peptide substrate (API) source of the mass spectrometer by direct infusion were calculated from plots of 1/velocity versus 1/[subusing a syringe pump (Harvard Instruments, Boston, MA) strate]. Standard assay conditions were used with subat 5 ml/min as previously described (Schnölzer et al., strate concentrations between 5 and 150 mM. Initial ve1992b). Data were acquired onto an Apple Macintosh IIfx locities were determined from cleavage product formacomputer and were processed using the data analysis tion analyzed by reverse-phase HPLC. Assays were set program MacSpec 3.11b25 (Sciex). Molecular masses up so that less than 20% of the substrate was cleaved. were calculated from the multiply charged ions using the Inhibition by pepstatin A. Cleavage assays were perHyperMass program (MacSpec 3.11b25) .
formed in the absence of NaCl using otherwise standard conditions. Pepstatin A concentrations were 1, 5, 10, 50, Folding of FIV PR and 100 mM, respectively. Quantitation of the cleavage reaction was as described above. Crude lyophilized FIV PR monomer (8 mg) was dissolved in 8 M urea, 0.1 M Na phosphate, pH 5.5, 1 mM RESULTS DTT to a concentration of 2 mg/ml and dialyzed at 4Њ against 500-ml batches of buffer containing 0.1 M sodium FIV PR amino acid sequence acetate, pH 5.5, 0.1 M NaCl, 0.1 mM EDTA, 0.5 mM DTT, 20% glycerol, and varying amounts of urea. The concenThe FIV PR is released from the region of the gagpol translation product corresponding to the N-terminal tration of urea in the dialysis buffer was reduced in each batch from 4, to 2, 1, 0.5, 0.25 M, and then no urea. The domain of the Pol polyprotein . We have previously defined the proteolytic processing sites resulting turbid solution (Ç16 ml) was centrifuged and the supernatant concentrated in P3 Centricon tubes to at the N-terminus of the PR and RT regions of the pol open reading frame (Elder et al., 1993) . In conjunction Ç2 ml. The final enzyme solution was adjusted to 30% glycerol and stored at 020ЊC.
with the translated cDNA sequence, these data define
Enzymatic activities
Specificity. Aliquots of the solution containing the folded synthetic FIV PR were assayed for the ability to cleave a synthetic peptide substrate corresponding to The N-terminus was established by Edman degradation of the PR the the matrix and capsid proteins cleavage site (MA/ purified from virus. The C-terminus was inferred from N-terminal CA) of the gag translation product (Fig. 2) . The sequence sequence analysis of FIV reverse transcriptase, adjacent to the PR of the substrate was (R)KEEGPPQAY Ç PIQTVNGPQY(R). The N-and C-terminal Arg residues were added to immass from the 116-amino-acid residue sequence shown is in agreement with the observed mass of the PR present in viral preparations prove the solubility of the peptide in the assay buffers.
[Observed: 13,235 { 2 Da; calculated: 13,234 Da (average isotope Specific cleavage products were observed. Mass speccomposition)] (Elder et al., 1993) . trometry on the collected fractions corresponding to the two products showed that cleavage occurred between the Tyr and Pro residues. This corresponds to the MA/ the 116-residue PR monomer amino acid sequence (Fig. CA cleavage site observed during viral maturation in vivo 1). Direct HPLC-mass spectrometry of the proteins from (Elder et al., 1993) . disrupted FIV virions identified a component in the exSynthetic peptide substrates corresponding to all the pected amount (i.e., in an amount comparable to other proteolytic processing sites of the FIV Gag and Gag-Pol similarly sized components of the virus pol-encoded enpolyprotein translation products were similarly examined zyme cassette, and in a much smaller amount than the (Table 1) . Specific cleavage was observed in each case, gag-derived structural proteins), with a mass in exact and for those substrates where the processing sites agreement with the sequence shown in Fig. 1 (Elder et were known from studies of the viral proteins (Elder et al., al., 1993 (Elder et al., al., ). 1993 , there was precise correlation between the studies with synthetic enzyme on synthetic substrate and the processing events in vivo. These results demonstrate FIV PR chemical synthesis that the synthetic FIV PR enzyme has specificity consistent with that required for viral maturation. The 116-amino-acid-residue PR was prepared by total
Kinetics. The rate of FIV PR activity was measured chemical synthesis using highly optimized stepwise using an HPLC assay, with the synthetic peptide analog solid-phase methods (Schnölzer et al., 1992a) . Synthesis of the MA/CA cleavage site as substrate (Fig. 2) . Enzystarted with the C-terminal Met residue, linked to a crossmatic activity was enhanced at increasing concentralinked polystyrene resin support. Chain assembly protions of NaCl; the maximum rate was obtained at Ç1.5 ceeded in stepwise fashion from the C-terminal to the M NaCl. This effect of salt concentration is similar to that amino-terminal residue, as described under Materials observed for the HIV-1 PR (Wondrak et al., 1991) . The and Methods. The machine-assisted synthesis proeffect of pH on activity was also measured, at constant ceeded at a rate of 75 residues per day, for a total of just over 1.5 days. Colorimetric assay for residual free amine (Sarin et al., 1981) showed that all amino acid additions had proceeded with ú99.7% yield. After completion of the assembly of the protected peptide chain, the DNP protecting group was removed from the His side chain of the resin-bound peptide, the N a -Boc was removed, and then the remainder of the protecting groups were removed and the peptide was simultaneously cleaved from the resin support, by treatment with HF plus scavenger.
The crude peptide product was examined by analytical reverse-phase HPLC and by electrospray mass spectrometry. Material of the target MW was observed (Found: 13,235 { 2 Da; calculated: 13,234.4 Da (average isotope composition)). Purification was performed by semiprep- give partially purified, folded FIV PR. 
FIV PR Cleavage of Synthetic Peptides Corresponding to in Vivo Processing Sites of the FIV Gag and Gag-Pol Polyproteins
Cleavage site Sequence Proteolytic activity
ionic strength. Under the conditions used, the enzyme products were determined in all cases by electrospray was saturated with substrate. Maximum enzymatic activmass spectrometry. Comparative measurements on ity was observed in the range of pH 5-6. Again, this is HIV-1 PR with HIV-1 synthetic peptide substrates were similar to the pH of maximum activity observed for the also performed. Some of the results are shown in Figs. 
HIV-1 PR, under comparable conditions (Hyland et al.,
4 and 5 and Table 2 . 1991a).
In the comparative activity studies of the two retroviKinetic parameters were determined on the same ral enzymes, two clear-cut results stand out: (i) FIV PR MA/CA peptide substrate (Fig. 2) . Measurements of will not cut an acetyl-(6-residue peptide)amide, initial rate as a function of substrate concentration whereas HIV-1 PR will cut the corresponding HIV 6-were performed by HPLC assay. Only the expected residue substrate (Kent, unpublished results; Wlocleavage at the Tyr Ç Pro site was observed. Typical dawer et al., 1989) ; FIV PR does, however, specifically saturation kinetics were observed (Fig. 3a) . A double cut an acetyl-(8-residue peptide)amide (Table 2) . Thus reciprocal plot (Fig. 3b ) of the data gave K m Ç10 mM there are significant differences in the substrate for the synthetic peptide analogue of the FIV MA/CA length requirement for the two enzymes. (ii) Although cleavage site. This K m is considerably higher than the both enzymes cut their corresponding Gag MA/CA high micromolar to millimolar K m values reported for cleavage sites between Tyr and Pro residues, the FIV the HIV-1 PR on unmodified peptide substrate ana-PR and HIV-1 PR show a strong preference for their logues of the HIV-1 MA/CA processing site (Hyland et own MA/CA Tyr Ç Pro substrates, despite four idential., 1991b; Ido et al., 1991; Griffiths et al., 1992) . The cal amino acids in the P3 -P3 positions (see Fig. 4 ). observed V max was similar to that of HIV-1 PR acting HIV-1 PR cuts the FIV MA/CA Tyr Ç Pro site approxion the analogous HIV-1 substrate. This V max measuremately 50 times slower than the FIV PR does (Fig. 4a) . ment is only approximate, because protein concentra-FIV PR cuts the HIV-1 MA/CA Tyr Ç Pro site approxition measurements for FIV PR have not yet been calimately 200 times slower than HIV-1 PR cuts the same brated. However, K m values are unaffected by concensubstrate (Fig. 4b) . The small difference in reciprocal tration of active enzyme. Further comparative studies, rates may be due to uncertainties in determining the now under way, will clarify this point.
concentration of active enzyme present in each case. It is interesting to note that FIV PR cleaves a synSubstrate specificity-comparison with HIV-1 PR thetic peptide spanning the NC/PR processing site [sequence Ac-Arg 1 -Arg-Ile-Gly 4 -Phe 5 -Val-Asn 7 Ç Tyr 8 -In addition to the determination of processing sites Asn-Lys-Val-Gly-Arg-Argramide; italicized residues in the viral Gag -Pol polyprotein described above, a added for solubility] at the expected Asn 7 Ç Tyr 8 , and variety of studies of the specificity of FIV PR were also between the Gly 4 Ç Phe 5 residues. An additional carried out on synthetic peptide substrates. Assays were analyzed by HPLC and identities of the cleavage cleavage site has been fortuitously created by the use HIV-1 PR cleaved the FIV CA/NC No. 1 peptide between the Leu Ç Ala and Leu Ç Leu peptide bonds (Fig. 5 and Table 2 ). This vividly demonstrates the similarities and differences in the specificity of the two enzymes on peptide substrates.
CONCLUSIONS
The FIV PR represents an important addition to the family of well-characterized retroviral proteases (Miller et al., 1989a,b) . As our understanding of the FIV PR increases, it will be important to relate that knowledge to the existing database for HIV-1 PR. The two enzymes have related activities, but at the same time we have defined critical differences, the most important being the observation that HIV-1 PR and FIV PR each show a strong preference for their own MA/CA substrates, despite an identical 0Tyr Ç Pro0 cleavage site in each case and substantially similar neighboring sequences. This type of subtle distinction in enzymatic properties makes the comparative study of the properties of FIV PR in the context of the HIV-1 PR an important model system for structure-based drug design. Further study will be facilitated by the recent completion of the crystal structure of FIV PR (Dunn et al., 1995) .
Currently, HIV-1 PR inhibitors show promise as effective AIDS therapeutics (Huff, 1991; Mitsuya et al., 1990; Vacca et al., 1994) , although the development of PR inhibitor-resistant strains of HIV-1 has been reported from clinical trials (Otto et al., 1993; El-Farrash et al., 1994) . This is not unexpected, since the HIV-1 reverse transcriptase has a high error rate that leads to rapid mutation of viral proteins subject to selective pressure. However, it does point to the utility of designing PR inhibitors which demonstrate inhibition against closely related PRs (i.e., HIV-1 and FIV) in that they may be better able to inhibit mutant forms of the PRs.
The observation that FIV PR requires a substrate 8
Initial velocity kinetic measurements at 37ЊC, pH 5.25, [NaCl] amino acids in length is important in that many PR inhibi- the S4 through S4 substrate binding pockets to be filled. Inhibitors based on an 8-amino-acid peptide may be more effective against FIV PR, as well as HIV-1 PR and of the N-terminal Arg residues to enhance solubility. mutant PRs. Initial results with pyrrolidine-containing a-A longer natural substrate sequence [Ac-Arg-Arg-Glyketo amide-based inhibitors (Slee et al., 1995) support Glu-Thr-Ile-Gly-Phe-Val-Asn Ç Tyr-Asn-Lys-Val-Glythis conclusion for FIV PR since addition of FIV-specific Arg-Argramide] did not display this phenomenon and amino acid residues to the primary core structure (Slee et was specifically processed only at the expected Asnal., 1995) increases the specificity for FIV PR dramatically Tyr cleavage site (Elder et al., 1993) .
(Wong, personal communication). In addition, with the CA/NC No. 1 cleavage site, the The results from the FIV and HIV-1 MA/CA cleavage enzymes exhibit somewhat different specificities: the FIV site are interesting in that they indicate the importance PR cuts the CA/NC No. 1 peptide between Leu Ç Leu of the P2 and P3 positions in the recognition and cleavresidues, while the HIV-1 PR cuts the corresponding HIVage of the peptide by the FIV and HIV-1 PRs. Incorporation of amino acid side chains at these positions, re-1 substrate between Leu Ç Ala residues. However, the sulting in a peptide that is cleaved equally by both PRs, By exploiting the similarities and differences in substrate specificity between the FIV and HIV-1 PRs, in conmay facilitate the development of peptide-based inhibitors that are equally effective for FIV PR and HIV-1 PR.
junction with the three-dimensional structures, it may be for retroviral PRs and resistant to mutations in the PR Griffiths, J. T., Phylip, L. H., Konvalinka, J., Strop, P., Gustchina, A., primary amino acid sequence, which to date have led to
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